No ASX ETF holds Imugene (IMU) as of 15 Oct 2026. Over the last year it fell 91.5%: on $10,000, −$9150. We explain 1 big move in that time.
About IMU
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$20.3m
- Held by0 ETFs
- Big moves1 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
Held by 0 ETFs
No ETF we track holds IMU directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did IMU fall 22.2% on 7 Jul 2026?
Imugene
Profit-taking and sentiment reversal after a short-term rally driven by positive clinical trial news earlier in the week, with no new catalysts to sustain the move
The recent news from late June to early July 2026 shows a string of positive clinical updates for Imugene's azer-cel BTKi trial, which likely caused a price run-up in preceding days. The sharp -22% drop with no company announcement on the day, and volume only modestly elevated at 1.56x normal, is consistent with a 'buy the rumour, sell the news' reversal or profit-taking after the positive news cycle peaked. The health sector index moved slightly positive (+0.41%) on the same day, ruling out sector-wide selling, and no new negative catalyst is visible in the evidence, leaving the most probable explanation as exhaustion of the news-driven rally rather than a specific negative event.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
Sector / macro signals